Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced plans to initiate registration-enabling studies for LYT-100, targeting idiopathic pulmonary fibrosis (IPF) through a 505(b)(2) pathway. This includes a dose-ranging study and a Phase 3 study. Recent results show that LYT-100 led to a 50% reduction in gastrointestinal adverse events compared to pirfenidone, the current standard treatment. Additionally, Dr. Paul Ford joins as SVP of Clinical Development to lead LYT-100's advancement, emphasizing the potential for improved tolerability and treatment adherence for IPF patients.
PureTech Health reported significant advancements in its clinical-stage therapeutic candidates across various indications. Key highlights include the progress of LYT-100 in Phase 2 trials for conditions related to inflammation and fibrosis, and the initiation of Phase 1 trials for LYT-200 and LYT-300. The company also noted successful scaling and launch preparations for its Founded Entities, including Gelesis’ Plenity®. The upcoming year is expected to be catalyst-rich with multiple study results promising to impact serious diseases. PureTech continues its commitment to innovative medicine, enhancing shareholder value.
PureTech Health plc presented preclinical proof-of-concept data for LYT-300 at the 60th American College of Neuropsychopharmacology Annual Meeting. LYT-300, an oral allopregnanolone, aims to treat neurological disorders such as depression and anxiety. The data show systemic exposure achieved after oral administration, enhancing the therapeutic potential of the Glyph™ technology platform. LYT-300 has advanced into a Phase 1 clinical study to assess safety and tolerability, with results expected in the second half of 2022.
PureTech Health plc has initiated a Phase 1 clinical study of LYT-300, an oral therapeutic candidate aimed at treating various neurological and neuropsychological conditions such as depression and anxiety. Leveraging the Glyph technology platform, LYT-300 is designed to enhance oral bioavailability compared to natural allopregnanolone, which suffers from poor absorption. The study will assess safety, tolerability, and pharmacokinetics, with results expected in the second half of 2022, potentially guiding future trials for broader indications.
PureTech Health announces the launch of Plenity, an FDA-cleared weight management aid, now available across the United States. The company also appointed Joy Bauer as Chief Nutrition Officer, who will provide nutrition counseling and education for Plenity members. Plenity is designed to help individuals manage weight by feeling satisfied with smaller portions. A subscription costs $98 for a four-week supply. This initiative aims to enhance healthcare access and support sustainable weight management.
PureTech Health's Founded Entity, Gelesis, announced a $30 million pre-order for its weight management product, Plenity®, from Ro, a leading direct-to-patient healthcare company. The new commercial manufacturing facility is now producing Plenity at scale to meet increasing demand, which has exceeded supply since its beta launch in 2020. Ro anticipates a staggering 1,500% YoY revenue growth for Plenity from December 2020 to December 2021, solidifying weight management as a top request on their platform.
PureTech Health plc announced positive results from a Phase 1 trial of LYT-100, demonstrating good tolerability and a favorable pharmacokinetic profile. The maximum tolerated dose was not reached, indicating further dose escalation studies are planned. The ongoing Phase 2 trial for Long COVID respiratory complications is on track for completion by year-end, with results expected in H1 2022. Future Phase 1 studies aim to clarify dosing and tolerability across various indications. These advancements underscore LYT-100's potential in treating inflammatory and fibrotic conditions.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) will participate in fireside chats at two key investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, and Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021.
Presenters include senior management members like George Farmer, Ph.D., and Daphne Zohar. Webcasts will be accessible via their investor relations page, reflecting their commitment to transparency and investor engagement.
PureTech Health is advancing its clinical trial for LYT-200, targeting challenging solid tumors like pancreatic cancer. The Phase 1/2 trial continues without reaching maximum tolerated dose, with initial results expected in H1 2022. The trial assesses LYT-200's safety, tolerability, and anti-tumor activity, both solo and with therapies like BeiGene's tislelizumab. Recently, LYT-200 received orphan drug designation from the FDA for pancreatic cancer, offering potential tax incentives and a chance for seven years of market exclusivity upon approval.
PureTech Health plc announced that the FDA granted orphan drug designation for its cancer treatment candidate, LYT-200, targeting pancreatic cancer. LYT-200, a human IgG4 monoclonal antibody, addresses poor survival rates in challenging solid tumors. Currently in a Phase 1/2 clinical trial, it has not yet reached the maximum tolerated dose. The designation allows for potential tax credits and seven years of market exclusivity upon approval. Topline results from the trial are expected in H1 2022.